Global Recognition For Aanjaneya Lifecare, Enters The Elite List of Golden Peacock Awards, Receives ‘Golden Peacock National Quality Award’

Aanjaneya Lifecare Selected in Pharmaceutical Sector For Robust Growth, Corporate Governance & Innovative Business Approach in tough Market Conditions.

Mumbai, Maharashtra, India, Saturday, February 09, 2013 — (Business Wire India) — Mumbai-based Aanjaneya Lifecare Limited BSE code (533412), the vertically integrated pharmaceutical company with manufacturing and marketing capabilities in APIs (Active Pharmaceutical Ingredients) with focus on anti-malarial, and finished dosage forms (FDFs) catering to various therapeutic segments, has received yet another feather in its cap at Golden Peacock National Quality Award – 2012 by winning the coveted title in Bangalore on 8th Feb 2013 in the presence of distinguished gathering of business leaders, jurists, academics, environmentalists, economists, legislators and policy makers during the 23rd World Congress on Leadership and Quality of Governance.

Aanjaneya Lifecare Ltd. has been selected as the winner of the ‘Golden Peacock National Quality Award’ on account of its formidable growth momentum under tough business environment for the year 2012 by the Awards Jury under the Chairmanship of Justice P. N. Bhagwati, former Chief Justice of India and Member, UN Human Rights Commission, Justice M N Venkatachaliah, chairman, IOD Advisory Council & former Chief Justice of India were among the judging panel for this year’s Golden Peacock Awards. BRAND image was among the most important criteria in the selection process. The Prestigious Award was conferred at a glittering award evening by Justice M N Venkatachaliah, Former Chief Justice of India at a power packed audience at Hotel Lalit Ashoka, Bangalore. The Coveted Award was received by Mr. Kashi Vishwanath, Chairman of Aanjaneya Lifecare Ltd.

On Friday, Aanjaneya declared the First 9 months report card where The Net Profit of Aanjaneya Lifecare Limited rose 8.19% to Rs 387.22 million in the first nine months ended 31st December 2012 as against Rs 357.91 million during the corresponding period of the last year. Total Sales during the first nine months ended 31st December 2012 was up 40.16% at Rs 4468.46 million as against Rs 3188.12 million for the same period last year.

Speaking on the Award, Dr. Kannan Vishwanath, Vice-Chairman & Managing Director, Aanjaneya Lifecare Ltd. said “This coveted title of Golden Peacock National Quality Awards reflect the resounding success of Aanjaneya Lifecare in the Pharmaceutical Industry in a short span of time & meeting the tough global challenges of keeping the winning Momentum, This Award is a standing testimony of the entire Aanjaneya Lifecare’s internal & external stakeholders who have reposed faith in our Organization”. While we are elated to receive this rare distinction, our responsibility increases manifold as the road ahead are full of challenges & plethora of opportunities Dr. Kannan added. The award is a validation for our innovative tool used to predict results and plan results with appropriate action plans is Scientific, Logical and well accepted and rightly acknowledged by a reputed team of assessors and distinguished Jury.” The Golden Peacock Awards were initiated by Institute of Directors, an apex association of Directors, in 1991. The Golden Peacock Awards Secretariat receives over 1000 entries each year for various awards, from over 25 countries worldwide. The Golden Peacock Awards is a set of prestigious national and global awards designed to improve productivity and quality in organizations.

About Aanjaneya Lifecare Limited:

Aanjaneya Lifecare Limited is a vertically integrated company having state-of-the-art; WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune. It is one of the largest contract manufacturers of codeine based cough syrups in India. The company exclusively manufactures the Codorex Brand of Zydus Cadilla and Codilite Brand of Tablets India Ltd. amongst others.The company raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities along with the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment.

The company with its manufacturing facilities -in Mahad, Hyderabad and Pune has to its credit many achievements.

• It is the world’s third-largest manufacturer of quinine salts in the world . Only nine companies globally manufacture quinine salts
• One of the largest codeine based formlulations manufacturer in the pharmaceutical sector
• One of the largest manufacturer of multi- flavored Lozenges in medical products in India
• The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients
• Anjaneya’s Nicco Nil lozenge is a first-of-its-kind hard boiled lozenge remedy for smoking de-addition; its Relacs is a first-time lozenge against insomnia and Arecta Plus, a lozenge variant for Erectile Dysfunction, is a first of its kind.

The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions. Anajaneyas Lifecare’s competence has been validated through patents granted by international and Indian authorities.

Highlights 2011-2012 for Active Pharmaceutical Ingredents

• Production of Quinine Sulphate increased 30% in 2011-2012
• Sales of Quinine Sulphate grew 45%
• Exports increased 250% from Rs 10 Crore to Rs 31 crore
• Added 35 international and 50 domestic clients
• Completed trials for Bromexine(expectorant)a new API that will be launched in 2012-2013

Highlights 2011-2012 for Finished Dosage Forms

• Launched ‘Rancorex’ an in-house codine based cough syrup brand for the first time in its history
• Received the Kenya PPB GMP approval from all facilities namely lozenges,liquids and ointments
• Received registration for ‘Arecta Plus'(a lozenge variant of Viagra tablets) from Sierrs Leone and Libya; received the first export order for this product to be executed in 2012-2013.

 

CONTACT DETAILS
Muddasir R, Head – Media Cell, Pharmaleaders House, +91 (80) 42138295, Mudasir.r@pharmaleaders.co.in